The diagnosis and treatment of growth hormone deficiency in adults

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 17, Issue 4, 2010, Pages 377-383

  Clemmons, David R ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

growth hormone stimulation testing and lipoprotein abnormalities; osteopenia; quality of life assessment

Indexed keywords

ESTROGEN; GROWTH HORMONE; LIPOPROTEIN; HUMAN GROWTH HORMONE; PROTEIN;

ARTHRALGIA; BODY COMPOSITION; BONE DENSITY; CARBOHYDRATE METABOLISM; CARPAL TUNNEL SYNDROME; CLINICAL TRIAL; DOSE RESPONSE; EDEMA; GROWTH HORMONE DEFICIENCY; HEADACHE; HORMONE SUBSTITUTION; HUMAN; INSULIN SENSITIVITY; JOINT STIFFNESS; LABORATORY DIAGNOSIS; LIPID METABOLISM; LIPOPROTEIN DEFICIENCY; MORTALITY; MYALGIA; PARESTHESIA; QUALITY OF LIFE; REVIEW; ADULT; CARDIOVASCULAR SYSTEM; DEFICIENCY; DRUG EFFECTS; ENDOCRINE SYSTEM EXAMINATION; EVALUATION STUDY; GROWTH DISORDERS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADULT; BODY COMPOSITION; CARBOHYDRATE METABOLISM; CARDIOVASCULAR SYSTEM; DIAGNOSTIC TECHNIQUES, ENDOCRINE; GROWTH DISORDERS; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; LIPID METABOLISM; PROTEINS;

EID: 77955774168     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e32833b6bc7     Document Type: Review

References (75)

1. Cohen LE, Radovick S. Molecular basis of combined pituitary hormone deficiency. Endocr Rev 2002; 3:431-442.
2. Moseley CT,Phillips JA 3rd. Pituitary gene mutations and the growth hormone pathway. Semin Reprod Med 2000; 18:21-29.
3. Bierich JR, Christie M, Heinrich JJ, Martinez AS. New observations on midline defects: coincidence of anophthalmos, microphthalmos and cryptophthalmos with hypothalamic disorders. Eur J Pediatr 1991; 150:246-249.
4. Gleeson HK, Gattamaneni HR, Smethurst L, et al. Reassessment of growth hormone status is required at final height in children treated with growth hormone. J Clin Endocrinol Metab 2004; 89:662-666.
5. Gasco V, Corneli G, Beccuti G, et al. Retesting the childhood-onset GHdeficient patient. Eur Soc Endocrinol 2008; 159:S45-S52.
6. Clayton PE, Cueno RC, Juul A, et al. Consensus statement on the management of the GH-treated adolescent in the transition to adult care. Eur J Endocrinol 2005; 152:165-170.
7. Maghnie M, Aimaretti G, Bellone S, et al. Diagnosis of GH deficiency in the transition period: accuracy of insulin tolerance test and insulin-like growth factor-I measurement. Eur J Endocrinol 2005; 152:589-596.
8. Sonksen PH. Replacement therapy in hypothalamo-pituitary insufficiency after childhood: management in the adult. Horm Res 1990; 33:45-51.
9. Berg C, Meinel T, Lahner H, et al. Recovery of pituitary function in the latepostoperative phase after pituitary surgery: results of dynamic testing in patients with pituitary disease by insulin tolerance test 3 and 12 months after surgery. Eur J Endocrinol 2010; 162:853-859.
10. Agha A, Sherlock M, Brennan S, et al. Hypothalamic-pituitary dysfunction after irradiation of nonpituitary brain tumors in adults. J Clin Endocrinol Metab 2005; 90:6355-6360.
11. Minniti G, Gilber DC, Brada M. Modern techniques for pituitary radiotherapy. Rev Endocr Metab Disord 2009; 10:135-144.
12. Agha A, Rogers B, Sherlock M. Anterior pituitary dysfunction in survivors of traumatic brain injury. J Clin Endocrinol Metab 2004; 89:4929-4936. (Pubitemid 39391430)
13. Webb SM, Strasburger CJ, Mo D, et al. Changing patterns of the adult growth hormone deficiency diagnosis documented in a decade-long global surveillance database. J Clin Endocrinol Metab 2009; 94:392-399.
14. Abs R, Mattsson AF, Bengtsson BA, et al. Isolated growth hormone (GH) deficiency in adult patients: baseline clinical characteristics and responses to GH replacement in comparison with hypopituitary patients. Growth Horm IGF Res 2005; 349-359.
15. Kreitschmann-Andermahr I, Suarez P, Jennings R, et al. GH/IGF-I regulation in obesity: mechanisms and practical consequences in children and adults. Horm Res Paediatr 2010; 73:153-160.
16. Salomon F, Ross C, Hesp R, Sonksen P. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 1989; 321:1799-1803.
17. Janssen YJ, Doornbos J, Roelfsema F. Changes in muscle volume, strength and bioenergetics during recombinant human growth hormone (GH) therapy in adults with GH deficiency. J Clin Endocrinol Metab 1999; 84:279-284.
18. Hoffman DM, OSullivan AJ, Freund J, Ho KK. Adults with growth hormone deficiency have abnormal body composition but normal energy metabolism. J Clin Endocrinol Metab 1995; 80:72-77.
19. Holmes SJ, Eocnomou G, Whitehouse RW, et al. Reduced bone mineral density in patients with adult onset growth hormone deficiency. J Clin Endocrinol Metab 1994; 78:669-674.
20. De Boer H, Blok GJ, Van Lingen A, et al. Consequences of childhood-onset growth hormone deficiency for adult bone mass. J Bone Miner Res 1994; 9:1319-1326.
21. Colao A, Di Somma C, Pivonello R. Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism. J Clin Endocrinol Metab 1999; 84:1919-1924.
22. Wuster C, Abs R, Bengtsson BA, et al. The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. J Bone Miner Res 2001; 16:398-405.
23. Bouillon R, Koledova E, Bezlepkina O, et al. Bone status and fracture prevalence in Russian adults with childhood-onset growth hormone deficiency. J Clin Endocrinol Metab 2004; 89:4993-4998.
24. Boger RH, Skamira C, Bode-Boger SM, et al. Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. A double-blind, placebo-controlled study. J Clin Invest 1996; 98:2706-2713.
25. Maison P, Chanson P. Cardiac effects of growth hormone in adults with growth hormone deficiency. Circulation 2003; 108:2648-2652.
26. Colao A, Di Somma C, Cuocolo A. Improved cardiovascular risk factors and cardiac performance after 12 months of growth hormone (GH) replacement in young adult patients with GH deficiency. J Clin Endocrinol Metab 2001; 86:1874-1881.
27. Murata M, Kaji H, Mizuno I, et al. A study of carotid intima-media thickness in GH deficient adults during onset among adults and children. Eur J Endocrinol 2003; 148:333-338.
28. Bates AS, Vant Hoff W, Jones PJ, Clayton RN. The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab 1996; 81:1169-1172.
29. Tomlinson JW, Holden N, Hills RK, et al., the West Midlands Prospective Hypopituitary Study Group. Association between premature mortality and hypopituitarism. Lancet 2001; 357:425-431.
30. Rosen T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990; 357:425-431.
31. Russell-Jones DL, Weissberger AJ, Bowes SB, et al. The effects of growth hormone on protein metabolism in adult growth hormone deficient patients. Clin Endocrinol 1993; 38:427-431.
32. Cueno RC, Salomon F, Watts GF, et al. Growth hormone treatment improves serum lipids and lipoprotein in adults with growth hormone deficiency. Metab Clin Exp 1993; 42:1519-1523.
33. De Boer H, Blok GJ, Voerman HJ, et al. Serum lipid levels in growth hormonedeficient men. Metab Clin Exp 1994; 43:199-203.
34. Christ ER, Cummings MH, Albany E, et al. Effects of growth hormone (GH) replacement therapy on very low density lipoprotein B100 kinetics in patients with adult GH deficiency: a stable isotope study. J Clin Endocrinol Metab 1999; 84:307-316.
35. Johannsson J, Fowelin J, Landin K, et al. Growth hormone-deficient adults are insulin-resistant. Metabolism 1995; 44:1126-1129.
36. Hew FL, Koschmann M, Christopher M, et al. Insulin resistance in growth hormone-deficient adults: defects in glucose utilization and glycogen synthase activity. J Clin Endocrinol Metab 1996; 81:555-564.
37. Rosilio M, Blum WF, Edwards DJ, et al. Long-term improvement of quality of life during growth hormone (GH) replacement therapy in adults with GH deficiency, as measured by questions on life satisfaction-hypopituitarism (QLS-H). J Clin Endocrinol Metab 2004; 89:1684-1693.
38. Burman P, Broman JE, Hetta J, et al. Quality of life in adults with growth hormone (GH) deficiency: response to treatment with recombinant human GH in a placebo-controlled 21-month trial. J Clin Endocrinol Metab 1995; 80:3585-3590.
39. Simpson H, Savine R, Sonksen P, et al. Growth hormone replacement therapy for adults: into the new millennium. Growth Horm IGF Res 2002; 12:1-33.
40. Growth Hormone Research Society. Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. J Clin Endocrinol Metab 1998; 83:379-381.
41. Hartman ML, Crowe BJ, Biller BMK, et al. Which patients do not require a growth hormone (GH) stimulation test for the diagnosis of adult GH deficiency? J Clin Endocrinol Metab 2002; 87:477-485.
42. Gleeson HK, Lissett CA, Shalet SM. Insulin-like growth factor-I response to a single bolus of growth hormone is increased in obesity. J Clin Endocrinol Metab 2005; 90:1061-1067.
43. Maccario M, Tassone F, Guana C, et al. Effects of short term administration of low dose rhGH on IGF-I levels in obesity and Cushings syndrome: indirect evaluation of sensitivity to GH. Eur J Endocrinol 2001; 144:251-256.
44. Ghigo E, Aimaretti G, Corneli G. Diagnosis of adult GH deficiency. Growth Horm IGF Res 2008; 18:1-16.
45. Biller BMK, Samuels MH, Zagar A, et al. Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency. J Clin Endocrinol Metab 2002; 87:2067-2079.
46. Frystyk J, Freda P, Clemmons DR. The current status of IGF-I assays: a 2009 update. Growth Horm IGF Res 2010; 20:8-18.
47. Bidlingmaier M, Freda PU. Measurement of human growth hormone by immunoassays: current status, unsolved problems and clinical consequences. Growth Horm IGF Res 2009; 20:19-25.
48. Bengtsson BA, Eden S, Lonn L, et al. Treatment of adults with growth hormone deficiency with recombinant human GH. J Clin Endocrinol Metab 1993; 76:309-317.
49. Johannsson G, Bjarnason R, Brammert M, et al. The individual responsiveness to growth hormone (GH) treatment in GH-deficient adults is dependent on the level of GH-binding protein, body mass index, age and gender. J Clin Endocrinol Metab 1996; 81:1575-1581.
50. Hoffman AR, Kuntze JE, Baptista J, et al. Growth hormone (GH) replacement therapy in adult-onset GH deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004; 89:2048-2056.
51. Gotherstrom G, Elbornsson M, Stibrant-Sunnerhagen K, et al. Ten years of growth hormone (GH) replacement normalizes muscle strength in GH-deficient adults. J Clin Endocrinol Metab 2009; 94:809-816.
52. Beauregard C, Utz AL, Schaub AE, et al. Growth hormone decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: a randomized, placebo-controlled study. J Clin Endocrinol Metab 2008; 93:2063-2071.
53. Jorgensen J, Thuesen L, Muller J, et al. Three years of growth hormone treatment in growth hormone deficient adults: near normalization of body composition and physical performance. Eur J Endocrinol 1994; 130:224-228.
54. Kearney T, de Gallegos CN, Proudler A, et al. Effects of short and long term density lipoprotein and low-density lipoprotein apoliprotein B100 kinetics in growth hormone deficient subjects. Metab Clin Exp 2003; 52:50-59.
55. Sesmilo G, Biller BM, Llevadot J, et al. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann Intern Med 2000; 86:5774-5781.
56. Thomas J, Monson JP. Adult GH deficiency throughout lifetime. Eur Soc Endocrinol 2009; 161:S97-S106.
57. Pfeifer M, Verhovec R, Zizek B, et al. Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults. J Clin Endocrinol Metab 1999; 84:453-457.
58. Borson-Chazol F, Serusclat A, Kalfallah Y, et al. Decrease in carotid intimamedia thickness after one growth hormone (GH) treatment in adults with GH deficiency. J Clin Endocrinol Metab 1999; 84:1329-1333.
59. Fowelin J, Attvall S, Lager I, Bengtsson BA. Effects of treatment with recombinant human growth hormone on insulin sensitivity and glucose metabolism in adults with growth hormone deficiency.Metab Clin Exp 1993; 42:1443-1447.
60. Woodmansee WW, Hartman ML, Lamberts SW, et al. Occurrence of impaired fasting glucose in GH-deficient adults receiving GH replacement compared with untreated subjects. Clin Endocrinol 2010; 72:59-69.
61. Johansson JO, Fowelin J, Landin K, et al. Growth hormone deficient adults are insulin resistant. Metab Clin Exp 1995; 44:1126-1129.
62. Baum HB, Biller BM, Finkelstein JS, et al. Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult onset growth hormone deficiency. A randomized, placebo-controlled trial. Ann Intern Med 1996; 125:883-890.
63. Biermasz NR, Hamby NA, Pereira AM, et al. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study. Clin Endocrinol 2004; 568-575.
64. Hogler W, Shaw N. Childhood growth hormone deficiency, bone density, structures and fractures: scrutinizing the evidence. Clin Endocrinol 2010; 72:281.
65. Holmer H, Svensson J, Rylander L, et al. Fracture incidence in GH-deficient patients on complete hormone replacement including GH. J Bone Min Res 2007; 12:1842-1850.
66. Murray RD, Skillicorn CJ, Howell SJ, et al. Influences on quality of life in GH deficient adults and their effect on response to treatment. J Clin Endocrinol Metab 2002; 87:4427-4428.
67. Gilchrist FJ, Murray RD, Shalet SM. The effect of long-term untreated growth hormone deficiency (GHD) and 9 years of GH replacement on the quality of life (Qol) of GH-deficient adults. Clin Endocrinol 2002; 57:363-370.
68. Filipsson H, Johannsson G. GH replacement in adults: interactions with other pituitary hormone deficiencies and replacement therapies. Eur J Endocrinol 2009; 161:S85-S95.
69. Agha A, Monson JP. Modulation of glucocorticoid metabolism by the growth hormone-IGF-1 axis. Clin Endocrinol 2007; 66:459-465.
70. Whitehead HN, Boreham C, McIlrath EM, et al. Growth hormone treatment of adults with growth hormone deficiency: results of a 13 month placebo controlled cross-over study. Clin Endocrinol 1992; 36:45-52.
71. Hoffman AR, Strasburger CJ, Zagar A, et al. Efficacy and tolerability of an individualized dosing regimen for adult growth hormone replacement therapy in comparison with fixed body weight-based dosing. J Clin Endocrinol Metab 2004; 89:3224-3233.
72. Holmes SJ, Shalet SM. Which adults develop side-effects of growth hormone replacement? Clin Endocrinol 1995; 43:143-149.
73. Radetti G, Gentili L, Lepidi M. Comment on growth hormone therapy and retinal changes mimicking diabetic retinopathy. J Clin Endocrinol Metab 2000; 85:923.
74. Swerdlow AJ, Reddinghus RE, Higgins CD, et al. Growth hormone treatment of children with brain tumors and risk of tumor recurrence. J Clin Endocrinol Metab 2000; 85:4444-4449.
75. Swerdlow AJ, Higgins CD, Aldard P, Preece MA. Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-1985: a cohort study. Lancet 2002; 360:273-277.